Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder, Scott D. Lunin, Alexander Zweibach, Mikhail Shtivelband, Patrick M. Travis, Jason C. Chandler, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Michael Weiss, Ian W. Flinn